Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
	Applicant Frans E. Janssens, et al.	
	Filing Date June 22, 2005	Group 1624
	Confirmation No. 1422	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
/B.C./	1	5,310,743	05/10/94	Schilling et al.	514	311
/B.C./	2	5,541,195	07/30/96	Schilling et al.	514	311
/B.C./	3	5,646,144	07/08/97	Schilling et al.	514	241

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES	Translation NO
/B.C./	4	01/30348 A1	05/03/01	WO	X	
/B.C./	5	02/062784 A1	08/15/02	WO	X	
/B.C./	6	02/32867 A1	04/25/02	WO	X	
/B.C./	7	97/16440 A1	05/09/97	WO	X	
** /B.C./	8	0 532 456 A1	03/17/93	EP		X

EXAMINER /Brenda Coleman/	DATE CONSIDERED 02/29/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
	Applicant Frans E. Janssens, et al.	
	Filing Date June 22, 2005	Group 1624
	Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	**9**	Aguiar, M. S. et al., "Effects of microinjections of the neuropeptide substance P in the dorsal periaqueductal gray on the behaviour of rats in the plus-maze test," *Physiol. Behav.*, 1996, 60, 1183-1186
/B.C./	**10**	Antiemetic Subcommittee, "Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)," *Annals Oncol.*, 1998, 9(8), 811-819
/B.C./	**11**	Arvanitis, L., "Efficacy and Tolerability of Four Novel Compounds in Schizophrenia: Results of the Metatrial Project," *ACNP Meeting*, December 10, 2001, Abstract 144, p. 178
/B.C./	**12**	Ballard, T. M. et al., "Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK_1 receptor antagonist," *Eur. J. Pharmacol.*, Feb. 2001, 412(3), 255-264
/B.C./	**13**	Bertand, C. et al., "Tachykinin and kinin receptor antagonists: therapeutic perspectives in allergic airway disease," *Trends Pharmacol. Sci.*, 1996, 17(7), 255-259
/B.C./	**14**	Brodin, E. et al., "Effects of sequential removal of rats from a group cage, and of individual housing of rats, on substance P, cholecystokinin and somatostatin levels in the periaqueductal grey and limbic regions," *Neuropeptides*, Apr. 1994, 26(4), 253-260
/B.C./	**15**	Campos et al., "Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone," *J. Clin. Oncol.*, 2001, 19, 1759-1767
/B.C./	**16**	Cocquyt, V. et al., "Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis," *Eur. J. Cancer*, May 2001, 37(7), 835-842
/B.C./	**17**	Culman, J. et al., "Central tachykinins: mediators of defence reaction and stress reactions," *Can. J. Physiol. Pharmacol.*, 1995, 73(7), 885-891

EXAMINER	/Brenda Coleman/	**DATE CONSIDERED**	02/29/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
	Applicant Frans E. Janssens, et al.	
	Filing Date June 22, 2005	Group 1624
	Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	**18**	DeMulder et al., "Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study," *Annals of Internal Medicine*, 1990, 113, 834-840
/B.C./	**19**	Elliott, P.J., "Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion," *Exp. Brain Res.* 1988, 73(2), 354-356
/B.C./	**20**	Giardina, G. et al., "Recent Advances in neurokinin-3 receptor antagonists," *Exp. Opin. Ther. Patents*, 2000, 10(6), 939-960
/B.C./	**21**	Hesketh et al., "Proposal for classifying the acute emetogenicity of cancer chemotherapy," *J. Clin. Oncol.*, 1997, 15(1), 103-109
/B.C./	**22**	Hesketh et al., "Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis," *J. Clin. Oncol.*, 1999, 17, 338-343
/B.C./	**23**	Kramer, M. S. et al., "Distinct mechanism for antidepressant activity by blockade of central substance P receptors," *Science*, 1998, 281(5383), 1640-1645
/B.C./	**24**	Krase et al., "Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats," *Behav. Brain. Res.*, 1994, 63, 81-88
/B.C./	**25**	Kris et al., "Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin," *J. Clin. Oncol.*, 1985, 3, 1379-1384
/B.C./	**26**	Lejeune, F. et al., "Selective, non-peptidergic Neurokinin$_1$ (NIK_1) Antagonists Enhance the Activity of Frontocortical Dopaminergic and Adrenergic, but not Serotonergic, Pathways in Rats," *Abstracts Soc. Neurosci.*, Abstract No. 477.1, November 2001, p. 1253
/B.C./	**27**	Longmore, J. et al., "Neurokinin Receptors," *DN&P*, 1995, 8(1), 5-23
/B.C./	**28**	Lundberg, J. M., "Tachykinins, sensory nerves, and asthma--an overview," *Can. J. Physiol. Pharmacol.*, 1995, 73(7), 908-914

EXAMINER	/Brenda Coleman/	**DATE CONSIDERED**	02/29/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
	Applicant Frans E. Janssens, et al.	
	Filing Date June 22, 2005	Group 1624
	Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	29	Maggi, C. A. et al., "The dual nature of the tachykinin NK_1 receptor," *Trends Pharmacol. Sci.*,1997, 18(10), 351-355
/B.C./	30	Maggi, C. A., "The mammalian tachykinin receptors," *Gen. Pharmacol.*, 1995, 26(5), 911-944
/B.C./	31	Mattson, R. J. et al., "An Improved Method for Reductive Alkylation of Amines Using Titanium (IV) Isopropoxide and Sodium Cyanoborohydride," *J. Org. Chem.*, 1990, 55, 2552-2554
/B.C./	32	Megens, A. A. et al., "Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist," *J. Pharmacol. Exp. Ther.*, 2002, 302(2), 696-709
/B.C./	33	Navari, R. M. et al., "Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group," *N. Engl. J. Med.*, 1999, 340(3), 190-195
/B.C./	34	Naylor, R. J. et al., "Emesis and anti-emesis," *Cancer Surv.*, 1994, 21, 117-135
/B.C./	35	Okano, S. et al., "Effects of TAK-637, a novel neurokinin-1 receptor antagonist, on colonic function in vivo," *J. Pharmacol. Exp. Ther.*, 2001, 298(2), 559-564
/B.C./	36	Piedimonte, G. et al., "A new NK_1 receptor antagonist (CP-99,994) prevents the increase in tracheal vascular permeability produced by hypertonic saline," *J. Pharmacol. Exp. Ther.*, 1993, 266, 270-273
/B.C./	37	Regoli, D. et al., "Receptors and antagonists for substance P and related peptides," *Pharmacol. Rev.*, 1994, 46(4), 551-599
/B.C./	38	Roila, F. "Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination," *Oncology*, 1993, 50(3), 163-167
/B.C./	39	Rudd, J. A. et al., "Effects of 5-HT_3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret," *Neuropharmacology*, 1994, 33(12), 1607-1608

EXAMINER /Brenda Coleman/	**DATE CONSIDERED** 02/29/2008

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. JANS-0079/ 1734-PCT-USA	Application No. 10/540,456
	Applicant Frans E. Janssens, et al.	
	Filing Date June 22, 2005	Group 1624
	Confirmation No. 1422	

NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/B.C./	**40**	Rudd, J. A. et al., "The action of the NK_1 tachykinin receptor antagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret," *Br. J. Pharmacol.*, 1994, 119(5), 931-936
/B.C./	**41**	Rupniak, N. M. et al., "Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists," *Trends Pharmacol. Sci.*, 1999, 20(12), 485-490
/B.C./	**42**	Sam, T. S. et al., "Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret," *Eur. J. Pharmacol.*, 2001, 417(3), 231-237
/B.C./	**43**	Shirayama, Y. et al., "Reduction of substance P after chronic antidepressants treatment in the striatum, substantia nigra and amygdala of the rat," *Brain Res.*, 1996, 739(1-2), 70-78
/B.C./	**44**	Stella, V. J. et al., "Prodrugs. Do they have advantages in clinical practice?" *Drugs*, 1985, 29, 455-473
/B.C./	**45**	Stella, V. J. et al., "Prodrugs", *Drug Delivery Systems*, 1985, pp. 112-176
/B.C./	**46**	Tattersall, F. D. et al., "Tachykinin NK_1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets," *Neuropharmacol.*, 1996, 35(8), 1121-1129
/B.C./	**47**	Tattersall, F. D. et al., "The novel NK_1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets," *Neuropharmacology*, 2000, 39(4), 652-663
/B.C./	**48**	Teixeira, R. M. et al., "Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice," *Eur. J. Pharmacol.*, 1996, 311, 7-14
/B.C./	**49**	Tonini, M. et al., "Tachykinin-dependent and -independent components of peristalsis in the guinea pig isolated distal colon," *Gastroenterol.*, 2001, 120, 938-945
/B.C./	**50**	Watson, J. W. et al., "The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK_1 receptor," *Br. J. Pharmacol.*, 1995, 115, 84-94
/B.C./	**51**	Wilson, C. O. et al., (Ed.), *Textbook of Organic Medicinal and Pharmaceutical Chemistry*, Seventh Edition, 1977, J. B. Lippincott Company, pp. 70-75

EXAMINER	/Brenda Coleman/	**DATE CONSIDERED**	02/29/2008